Cyclosporin Brain Protection: Swedish Research Wins USA Patent for Maas BiolAB of Hawaii.HONOLULU--(BW HealthWire)--Oct. 26, 1999-- Patent 5,972,924 was granted today by the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property to Maas BiolAB, LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control for cyclosporin neuroprotection, announced Marcus Keep M.D., chief executive officer. Acute brain attacks potentially treatable with cyclosporin include stroke, brain and spinal cord injury Spinal Cord Injury Definition Spinal cord injury is damage to the spinal cord that causes loss of sensation and motor control. Description Approximately 10,000 new spinal cord injuries (SCIs) occur each year in the United States. , and chronic brain diseases include Alzheimer's, Parkinson's, Huntington's and ALS Als (äls), Ger. Alsen, island, 121 sq mi (313 sq km), Sønderjylland co., S Denmark, in the Lille Bælt, separated from the mainland by the narrow Alensund. . Cyclosporin protects the brain by interfering with the energy-producing mitochondria. It keeps mitochondria viable during stroke, and blocks mitochondrial mitochondrial pertaining to mitochondria. mitochondrial RNAs a unique set of tRNAs, mRNAs, rRNAs, transcribed from mitochondrial DNA by a mitochondrial-specific RNA polymerase, that account for about 4% of the total cell RNA that cytochrome c release and apoptotic cell death. It also protects brain by blocking calcineurin enzyme activity and nitric oxide production. "Our USA patent joins an explosion of scientific pre-clinical research publications in 1999 showing cyclosporin to be the most potent neuroprotectant drug in neurological emergencies," said Eskil Elmer, Ph.D. Maas Scientific Director. Cyclosporin is the first member of neuroprotective drugs called "Neuroimmunophilin ligands." Others are Guilford's FK-Binding Proteins (FKBPs) licensed to Amgen for up to $500 million, Vertex's FKBPs licensed to Schering-Plough for $88 million, and Fujisawa's FK506 (Prograf), for which they hold the stroke patent themselves. Novartis' cyclosporin production patent expired in 1995, and several companies now manufacture it. "The USA patent strengthens our intellectual property portfolio," said Helmuth von Moltke Helmuth von Moltke can refer to these people:
|
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion